MedTrace Logo

Understanding How Ketamine Brings About Rapid Improvement in OCD

NCT02624596 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-05-31

No results posted yet for this study

Summary

The purpose of this study is to understand how ketamine brings about rapid improvement in Obsessive-Compulsive Disorder (OCD) symptoms.

Conditions

  • Obsessive-Compulsive Disorder

Interventions

DRUG

Ketamine

OCD patients in this arm will receive 0.5mg/kg of ketamine - one single infusion

DRUG

Midazolam

OCD patients in this arm will receive 0.045mg/kg of midazolam - one single infusion

Sponsors & Collaborators

Principal Investigators

  • Carolyn I Rodriguez, MD, PhD · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02624596 on ClinicalTrials.gov